The FDA has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to NEU-001, a novel therapy developed by Neurenati Therapeutics for Hirschsprung disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.